Immuno-Oncology

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

The FDA has approved the combination of nivolumab and ipilimumab for the first-line treatment of patients with PD-L1–positive metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

The first patient has been dosed in a phase 1/2 trial of TJD5 in Chinese patients with advanced solid tumors, according to I-Mab, the company developing the CD73 antibody.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.